ALLMedicine™ Alpha-1 Antitrypsin Deficiency Center
Research & Reviews 313 results
https://clinicaltrials.gov/ct2/show/NCT04262284
Aug 2nd, 2022 - According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions...
https://doi.org/10.1016/j.cld.2022.03.004
Clinics in Liver Disease; Suri A, Patel D et. al.
Jul 23rd, 2022 - Liver disease in homozygous ZZ alpha-1 antitrypsin (AAT) deficiency occurs due to the accumulation of large quantities of AAT mutant Z protein polymers in the liver. The mutant Z protein folds improperly during biogenesis and is retained within th...
https://doi.org/10.1097/MEG.0000000000002395
European Journal of Gastroenterology & Hepatology; Shen K, Lyu R et. al.
Jul 9th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is an uncommon but underdiagnosed cause of cirrhosis and lacks medical treatment options. It is important to recognize risk factors that contribute to disease progression and liver transplantation. We aimed to...
https://clinicaltrials.gov/ct2/show/NCT05195853
Jun 30th, 2022 - Lung transplantation is the curative treatment for end-stage respiratory failure involving highly selected patients. In 2018, the International Transplant Registry counts 69200 lung transplants among 260 transplant centers. Between 2010 and June 2...
https://clinicaltrials.gov/ct2/show/NCT05146882
Jun 27th, 2022 - This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.
Guidelines 3 results
https://doi.org/10.1016/j.clinre.2021.101768
Clinics and Research in Hepatology and Gastroenterology; Sobesky R, Guillaud O et. al.
Aug 1st, 2021 - Rare genetic liver diseases can result in multi-systemic damage, which may compromise the patient's prognosis. Wilson's disease and alpha-1 antitrypsin deficiency must be investigated in any patient with unexplained liver disease. Cystic fibrosis ...
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.
Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373286
Canadian Respiratory Journal; Marciniuk DD, Hernandez P et. al.
Apr 27th, 2012 - Alpha-1 antitrypsin (A1AT) functions primarily to inhibit neutrophil elastase, and deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). Severe A1AT deficiency occurs in one in 5000 to one in 5500 o...
Clinicaltrials.gov 34 results
https://clinicaltrials.gov/ct2/show/NCT04262284
Aug 2nd, 2022 - According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions...
https://clinicaltrials.gov/ct2/show/NCT05195853
Jun 30th, 2022 - Lung transplantation is the curative treatment for end-stage respiratory failure involving highly selected patients. In 2018, the International Transplant Registry counts 69200 lung transplants among 260 transplant centers. Between 2010 and June 2...
https://clinicaltrials.gov/ct2/show/NCT05146882
Jun 27th, 2022 - This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.
https://clinicaltrials.gov/ct2/show/NCT03946449
May 4th, 2022 - Participants will be enrolled to receive multiple subcutaneous injections of ARO-AAT. All eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. All participants will undergo an End of Stud...
https://clinicaltrials.gov/ct2/show/NCT01148550
Apr 22nd, 2022 - This study will be conducted as part of the NIH-supported Childhood Liver Disease Research and Education Network (ChiLDREN). ChiLDREN is investigating rare cholestatic liver diseases of childhood: alpha-1 antitrypsin deficiency (A1AT), Alagille's ...
News 46 results
https://www.medscape.com/viewarticle/973787
May 11th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U.S. Preventive Services Task Force (USPSTF) reassessment of its 2016 screening recommendations. The new recommendation is in line...
https://www.mdedge.com/chestphysician/article/254452/copd/copd-screening-asymptomatic-adults-uspstf-weighs-again
Mark S. Lesney, PhD, MDedge News
May 10th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U. S.
https://www.medpagetoday.com/infectiousdisease/covid19/93049
Jun 11th, 2021 - Note that some links may require registration or subscription. Here we go again. As cruise lines struggle to recover from COVID-19, two passengers aboard a Royal Caribbean ship tested positive for coronavirus; all crew and passengers over 16 were ...
https://www.onclive.com/view/hcc-etiologic-risk-factors-and-global-prevalence
Apr 2nd, 2021 - Minsig Choi, MD: What are the etiology risk factors in the development of hepatocellular cancer? We all know that hepatocellular cancer or liver cancer is caused by a chronic irritation or inflammations. Usually the most common causes of this irri...
https://www.medscape.com/viewarticle/938411
Oct 2nd, 2020 - NEW YORK (Reuters Health) - Ethnic differences in the frequencies of alpha-1 antitrypsin deficiency alleles might contribute to national differences in COVID-19 fatality rates, researchers report. "It was interesting to see how one point mutation ...